Zortress Approval History
FDA Approved: Yes (First approved April 22, 2010)
Brand name: Zortress
Generic name: everolimus
Dosage form: Tablets
Previous Name: Certican
Company: Novartis Pharmaceuticals Corporation
Treatment for: Organ Transplant, Rejection Prophylaxis
Zortress (everolimus) is an oral inhibitor of the mTOR pathway indicated for the prevention of rejection of kidney transplants in adult patients at low-to-moderate immunologic risk.
Development History and FDA Approval Process for Zortress
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.